Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Orthofix (OFIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. If you currently own Orthofix stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). If you currently own shares of Orthofix Medical stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=19330 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why R.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). If you currently own shares of Orthofix Medical stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=19330 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why R.

Orthofix Medical Inc. (OFIX) Q4 2025 Earnings Call Transcript

Orthofix (OFIX) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.02 per share a year ago.

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2025, provided full-year 2026 financial guidance and updated its three-year financial targets. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Fourth quarter reported 2025 net sales of $219.